New therapies for type 2 diabetes based on glucagon-like peptide 1.

Journal Article (Review)

Cells in the gastrointestinal tract secrete several hormones that stimulate insulin secretion, one of which is glucagon-like peptide (GLP-1). Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes. One such compound, exenatide (Byetta), has recently become available, and others are in clinical development.

Duke Authors

Cited Authors

  • Salehi, M; D'Alessio, DA

Published Date

  • April 2006

Published In

Volume / Issue

  • 73 / 4

Start / End Page

  • 382 - 389

PubMed ID

  • 16610399

Electronic International Standard Serial Number (EISSN)

  • 1939-2869

International Standard Serial Number (ISSN)

  • 0891-1150

Language

  • eng